LABU News and Press, Direxion Daily S&P Biotech Bull 3X Shares From 08/06/22

Gainers: Direxion Daily S&P Biotech Bull 3x Shares ETF ( LABU ) +44% . Axs 2X Innovation ETF ( TARK ) +22% . ProShares Trust II - ProShares UltraPro 3x Short Crude Oil ETF ( OILD ) +22% . Bank of Montreal Microsectors Travel 3X Inverse ( FLYU ...

I believe small- and mid-cap biotech bottomed in May through June and has outperformed the broader market since then. Biotech continues to show strong relative outperformance versus the market and most sectors/industries. Biotech strength is likely to continue through the second h...

Drift review of 22 leveraged ETFs. ZSL and LABU show significant monthly decay. LABD and SOXS have the worst 12-month drifts in my list. Historical decay of SDS is close to zero on average, but it may hurt on limited periods of time. The ProShares UltraShort S&P ...

After the FDA provided an update on the agency's response to the monkeypox outbreak on July 29th, investors misunderstood the FDA's statements, and the stock sold off 33% and shortly reverted. SIGA's monkeypox treatment TPOXX is already approved in the U.S., EU, and Canada for smallpo...

Today, we take a look at Adicet Bio for the first time. The company is pioneering what it hopes will be among the next wave of CAR-T therapies and is advancing its lead candidate. An investment analysis follows in the paragraphs below. Don't live the same year 75 tim...

Our Marketplace Contributor Roundtable Series finishes with a wide range of coverage. Seven of our top contributors discuss what they're looking for this earnings season in value, commodities, and macro. As always, SA Marketplace articles are never paywalled. ~ By Tim ...

Incyte is outperforming the SP 500. Institutions are accumulating shares. My price target on INCY is $100. Incyte Corp. is Moving Higher Incyte Corporation ( INCY ) is a biopharmaceutical company that is outperforming the SP 500 index. There are several bullish i...

Kura's Phase 1b data for menin inhibitor Ziftomenib in treating NPM1 mutant and KMT2A rearranged acute myeloid leukemia, or AML, is expected this quarter. Prior data showed a complete remission in a NPM1 mutant AML patient who had failed 7 prior lines of treatment. The target mark...

Our next Marketplace Contributor Roundtable Series will be a Q2 Earnings Preview. To kick off, we have responses from 16 Marketplace contributors on Tech and Growth stocks. The series continues next week with everything from Dividends to Value Stocks and Macro coverage. As alw...

Resubmission of BLA for DAXI for glabellar lines achieved, PDUFA date established for September 8, 2022. The global Botulinum Toxin market is expected to reach $7.71 billion by 2027. Since launch of the RHA Collection, sales reached $100 million, with first-quarter revenue totalin...